Neisseria meningitidis compositions and methods thereof
Kathrin Ute Jansen, New York, NY (US); Annaliesa Sybil Anderson, Upper Saddle River, NJ (US); Judith Absalon, New York, NY (US); Jose Miguel Aste-Amezaga, Harleysville, PA (US); Johannes Frederik Beeslaar, Farnham (GB); David Cooper, Monroe, NY (US); John Erwin Farley, Chapel Hill, NC (US); Leah Diane Fletcher, Geneseo, NY (US); Shannon Lea Harris, Nanuet, NY (US); Thomas Richard Jones, Bluffton, SC (US); Isis Kanevsky, New York, NY (US); Lakshmi Khandke, Nanuet, NY (US); Paul Liberator, Holmdel, NJ (US); John Lance Perez, Doylestown, PA (US); Lynn Marie Phelan, Lake Hiawatha, NJ (US); and Gary Warren Zlotnick, San Antonio, TX (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by PFIZER INC., New York, NY (US)
Filed on Sep. 17, 2020, as Appl. No. 17/24,618.
Application 17/024,618 is a division of application No. 16/704,701, filed on Dec. 5, 2019, granted, now 10,813,989.
Application 16/704,701 is a continuation of application No. 16/196,150, filed on Nov. 20, 2018, granted, now 10,543,267, issued on Jan. 28, 2020.
Application 16/196,150 is a continuation of application No. 15/883,334, filed on Jan. 30, 2018, granted, now 10,183,070, issued on Jan. 22, 2019.
Claims priority of provisional application 62/623,233, filed on Jan. 29, 2018.
Claims priority of provisional application 62/613,945, filed on Jan. 5, 2018.
Claims priority of provisional application 62/503,295, filed on May 8, 2017.
Claims priority of provisional application 62/452,963, filed on Jan. 31, 2017.
Prior Publication US 2020/0405838 A1, Dec. 31, 2020
1. A method of inducing an immune response against a Neisseria meningitidis serogroup A strain expressing B16 factor H binding protein in a human comprising mixing (a) a composition comprising (i) a first lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1; (ii) a second lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2; (iii) a Neisseria meningitidis serogroup A (MenA) capsular saccharide conjugated to an adipic acid dihydrazide (ADH) linker, wherein the linker is conjugated to tetanus toxoid (TT); (iv) a Neisseria meningitidis serogroup C (MenC) capsular saccharide conjugated to an ADH linker, wherein the linker is conjugated to tetanus toxoid (TT); (v) a Neisseria meningitidis serogroup W135 (MenW) capsular saccharide conjugated to tetanus toxoid (TT) (MenW-TT conjugate); and (vi) a Neisseria meningitidis serogroup Y (MenY) capsular saccharide directly conjugated to tetanus toxoid (TT) (MenY-TT conjugate); and (b) administering an effective amount of the composition to the human, wherein the composition comprises about 5 μg of the MenA capsular saccharide conjugated to about 7.5 μg of the TT; about 5 μg of the MenC capsular saccharide conjugated to about 7.5 μg of the TT; about 5 μg of the MenW capsular saccharide conjugated to about 3.75 μg of the TT; and about 5 μg of the MenY capsular saccharide conjugated to about 3.25 μg of the TT per dose; and further comprises aluminum.